BR9508402A - Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união - Google Patents
Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de uniãoInfo
- Publication number
- BR9508402A BR9508402A BR9508402A BR9508402A BR9508402A BR 9508402 A BR9508402 A BR 9508402A BR 9508402 A BR9508402 A BR 9508402A BR 9508402 A BR9508402 A BR 9508402A BR 9508402 A BR9508402 A BR 9508402A
- Authority
- BR
- Brazil
- Prior art keywords
- bonding binder
- pharmaceutical composition
- composition kit
- bonding
- factor construction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27356794A | 1994-07-11 | 1994-07-11 | |
PCT/US1995/007439 WO1996001653A1 (en) | 1994-07-11 | 1995-06-07 | Methods and compositions for the specific coagulation of vasculature |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9508402A true BR9508402A (pt) | 1997-10-21 |
Family
ID=23044480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9508402A BR9508402A (pt) | 1994-07-11 | 1995-06-07 | Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0771216B9 (pt) |
JP (5) | JP4361133B2 (pt) |
CN (1) | CN1162184C (pt) |
AT (1) | ATE198712T1 (pt) |
AU (1) | AU702250B2 (pt) |
BR (1) | BR9508402A (pt) |
CA (1) | CA2194369C (pt) |
DE (1) | DE69519929T2 (pt) |
DK (1) | DK0771216T3 (pt) |
ES (1) | ES2153483T3 (pt) |
GR (1) | GR3035617T3 (pt) |
HK (1) | HK1014496A1 (pt) |
HU (1) | HU220347B (pt) |
MX (1) | MX9700312A (pt) |
NZ (1) | NZ288883A (pt) |
PT (1) | PT771216E (pt) |
WO (1) | WO1996001653A1 (pt) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022541A (en) * | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
CA2236155A1 (en) * | 1995-11-22 | 1997-05-29 | Oklahoma Medical Research Foundation | Assay for blood clotting factors viii and ix |
ATE244579T1 (de) * | 1997-01-22 | 2003-07-15 | Univ Texas | Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
EE200000574A (et) | 1998-03-31 | 2002-10-15 | Dupont Pharmaceuticals Company | Farmatseutilised ühendid angiogeensete häirete kuvamiseks |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6534035B1 (en) | 1998-05-29 | 2003-03-18 | President And Fellows Of Harvard College | Methods of inhibiting clot formation |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
JP4743672B2 (ja) | 1998-07-13 | 2011-08-10 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | アミノリン脂質に対する抗体を用いる癌処置方法 |
ES2188202T3 (es) | 1998-07-13 | 2003-06-16 | Univ Texas | Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos. |
EP1520588B1 (en) * | 1998-07-13 | 2014-12-24 | Board Of Regents, The University Of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
IL142864A0 (en) * | 1998-11-12 | 2002-03-10 | Novolytics Inc | Compositions and methods for producing vascular occlusion |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
NZ511677A (en) | 1998-12-18 | 2003-10-31 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
WO2000035887A2 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
IT1307864B1 (it) * | 1999-04-20 | 2001-11-19 | Istituto Naz Per La Ricerca Su | Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di |
US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
ATE398633T1 (de) * | 1999-07-01 | 2008-07-15 | Univ Yale | Neovaskulär gerichtete immunkonjugate |
US6924359B1 (en) | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
DE60121733T2 (de) | 2000-02-24 | 2007-08-09 | Philogen S.P.A. | Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen |
AU2006200762B2 (en) * | 2000-02-24 | 2008-08-21 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
WO2003035688A2 (en) * | 2001-10-26 | 2003-05-01 | Novartis Pharma Gmbh | Targeted thrombosis by tissue factor polypeptides |
NZ596825A (en) | 2002-07-15 | 2013-06-28 | Univ Texas | Duramycin peptides and their use in imaging |
US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
JP5438880B2 (ja) * | 2003-10-10 | 2014-03-12 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
ES2362881T3 (es) | 2003-12-09 | 2011-07-14 | Engeneic Molecular Delivery Pty Ltd. | Administración génica dirigida a células de mamífero no fagocíticas a través de minicélulas intactas obtenidas de bacterias. |
EP1819731A4 (en) | 2004-12-08 | 2013-02-13 | Immunomedics Inc | METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER |
US20080199499A1 (en) * | 2005-01-12 | 2008-08-21 | Proteonova, Inc. | Method for Making Targeted Therapeutic Agents |
US10206998B2 (en) | 2005-01-12 | 2019-02-19 | Proteonova, Inc. | Modular targeted therapeutic agents and methods of making same |
DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
AU2007232873B2 (en) | 2006-03-31 | 2014-02-20 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN105177091A (zh) | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
JP5800458B2 (ja) * | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP2614837A1 (en) | 2007-11-09 | 2013-07-17 | Affitech Research AS | Anti-VEGF antibody compositions and methods |
US8815240B2 (en) | 2008-03-19 | 2014-08-26 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
CN104045716A (zh) * | 2008-05-16 | 2014-09-17 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
WO2010115866A1 (en) * | 2009-04-06 | 2010-10-14 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
JP2009292822A (ja) * | 2009-07-23 | 2009-12-17 | Chugai Pharmaceut Co Ltd | 機能蛋白質を代替する二種特異性抗体 |
EP3778917A3 (en) * | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
EP3281956A3 (en) | 2010-06-15 | 2018-04-18 | Genmab A/S | Human antibody drug conjugates against tissue factor |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
MY166429A (en) | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
CN103969228A (zh) * | 2013-02-04 | 2014-08-06 | 百奥泰生物科技(广州)有限公司 | 一种整合素GP IIb/IIIa特异性结合分子巴替非班的生物学效应检测方法 |
KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
KR102074421B1 (ko) | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
CN104045717B (zh) * | 2014-07-08 | 2016-07-06 | 北京华安科创生物技术有限公司 | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
AU2016248817A1 (en) * | 2015-04-17 | 2017-08-17 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
CN109661241A (zh) | 2016-09-06 | 2019-04-19 | 中外制药株式会社 | 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法 |
US20190248920A1 (en) * | 2016-09-23 | 2019-08-15 | Csl Limited | Coagulation factor binding proteins and uses thereof |
EP3617316A4 (en) * | 2017-04-27 | 2020-12-23 | Chugai Seiyaku Kabushiki Kaisha | COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS |
AR113142A1 (es) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo |
CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
KR20210069639A (ko) * | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
WO2020047473A1 (en) * | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
CN109999182B (zh) * | 2019-03-29 | 2023-03-07 | 四川大学华西医院 | 凝血因子在制备抗肿瘤药物中的应用 |
AU2020259982A1 (en) | 2019-04-17 | 2021-10-28 | Novo Nordisk A/S | Bispecific antibodies |
US20210268022A1 (en) * | 2020-02-11 | 2021-09-02 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001145A1 (en) * | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
TW212184B (pt) * | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
AU2861692A (en) * | 1991-10-18 | 1993-05-21 | Beth Israel Hospital Association, The | Vascular permeability factor targeted compounds |
WO1993017715A1 (en) * | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
-
1995
- 1995-06-07 MX MX9700312A patent/MX9700312A/es unknown
- 1995-06-07 DK DK95923817T patent/DK0771216T3/da active
- 1995-06-07 NZ NZ288883A patent/NZ288883A/xx not_active IP Right Cessation
- 1995-06-07 PT PT95923817T patent/PT771216E/pt unknown
- 1995-06-07 AT AT95923817T patent/ATE198712T1/de active
- 1995-06-07 EP EP95923817A patent/EP0771216B9/en not_active Expired - Lifetime
- 1995-06-07 CN CNB951948016A patent/CN1162184C/zh not_active Expired - Fee Related
- 1995-06-07 DE DE69519929T patent/DE69519929T2/de not_active Expired - Lifetime
- 1995-06-07 CA CA002194369A patent/CA2194369C/en not_active Expired - Fee Related
- 1995-06-07 AU AU28249/95A patent/AU702250B2/en not_active Ceased
- 1995-06-07 JP JP50429996A patent/JP4361133B2/ja not_active Expired - Fee Related
- 1995-06-07 ES ES95923817T patent/ES2153483T3/es not_active Expired - Lifetime
- 1995-06-07 HU HU9700084A patent/HU220347B/hu not_active IP Right Cessation
- 1995-06-07 WO PCT/US1995/007439 patent/WO1996001653A1/en active IP Right Grant
- 1995-06-07 BR BR9508402A patent/BR9508402A/pt not_active IP Right Cessation
-
1998
- 1998-12-28 HK HK98115809A patent/HK1014496A1/xx not_active IP Right Cessation
-
2001
- 2001-03-21 GR GR20010400463T patent/GR3035617T3/el unknown
-
2002
- 2002-06-05 JP JP2002164988A patent/JP2003055398A/ja not_active Withdrawn
-
2006
- 2006-07-21 JP JP2006200132A patent/JP2007016033A/ja not_active Withdrawn
-
2008
- 2008-07-30 JP JP2008196859A patent/JP2008297319A/ja not_active Withdrawn
-
2009
- 2009-09-09 JP JP2009208734A patent/JP4932883B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0771216A1 (en) | 1997-05-07 |
GR3035617T3 (en) | 2001-06-29 |
WO1996001653A1 (en) | 1996-01-25 |
JP2008297319A (ja) | 2008-12-11 |
HUT76970A (hu) | 1998-01-28 |
MX9700312A (es) | 1997-07-31 |
HU220347B (hu) | 2001-12-28 |
JPH10505327A (ja) | 1998-05-26 |
AU2824995A (en) | 1996-02-09 |
PT771216E (pt) | 2001-07-31 |
ES2153483T3 (es) | 2001-03-01 |
JP2003055398A (ja) | 2003-02-26 |
DE69519929D1 (de) | 2001-02-22 |
HU9700084D0 (en) | 1997-02-28 |
JP4932883B2 (ja) | 2012-05-16 |
CA2194369A1 (en) | 1996-01-25 |
HK1014496A1 (en) | 1999-09-30 |
EP0771216B1 (en) | 2001-01-17 |
ATE198712T1 (de) | 2001-02-15 |
DE69519929T2 (de) | 2001-05-23 |
DK0771216T3 (da) | 2001-02-05 |
JP4361133B2 (ja) | 2009-11-11 |
JP2007016033A (ja) | 2007-01-25 |
EP0771216B9 (en) | 2003-01-02 |
CN1162267A (zh) | 1997-10-15 |
CN1162184C (zh) | 2004-08-18 |
NZ288883A (en) | 1998-12-23 |
JP2009298805A (ja) | 2009-12-24 |
CA2194369C (en) | 2004-08-31 |
AU702250B2 (en) | 1999-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9508402A (pt) | Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união | |
CY1111863T1 (el) | Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων | |
ATE265863T1 (de) | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung | |
SG196688A1 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
FI971406A (fi) | TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
CY1110505T1 (el) | Ανθρωπινα αντισωματα dr4 και χρησεις αυτων | |
DE69828614D1 (de) | Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 | |
DE69942802D1 (de) | Trifunktionales reagenz zur verbindung von biomolekülen | |
NO971341L (no) | Promoter for reseptor tyrosinkinase TIE | |
DE69127334D1 (de) | Verabreichung von Mitteln | |
FI982745A (fi) | TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt" | |
AU9363398A (en) | Hepatitis c receptor protein cd81 | |
DE69737651D1 (de) | Cortistatin: neuropeptide, zusammensetzungen und methoden | |
DE69120287T2 (de) | Aminosulfonylharnstoff-acat-inhibitoren | |
DE69912827D1 (de) | "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen | |
TR200000416T2 (tr) | Neisseria loctoferrin bağlayıcı protein. | |
DK0789583T3 (da) | Fremgangsmåder og kits som anvender makrofagstimulerende protein | |
CY1114280T1 (el) | Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
FF | Decision: intention to grant | ||
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2259 DE 22-04-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/30 (2006.01), A61K 47/68 (2017.0 |